Alembic Pharmaceuticals has successfully completed an unannounced onsite Bioequivalence inspection conducted by United States Food and Drug Administration (USFDA). The inspection was conducted from August 31, 2026 to September 10, 2026 at the company’s Bioequivalence Facility located in Vadodara, Gujarat, and concluded with no Form 483 observations.
Alembic Pharmaceuticals is involved in manufacturing and marketing of India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities.
